FDA cracks down on GLP‑1s

The Food and Drug Administration has warned 30 telehealth companies to stop illegally marketing compounded GLP-1 weight-loss drugs as if they were approved medicines. (fda.gov) The agency said on March 3 that the companies made “false and misleading” claims on their websites about compounded GLP-1 products, which are not reviewed by the FDA for safety, effectiveness, or quality before sale. (fda.gov) GLP-1 drugs mimic a gut hormone that helps control blood sugar and appetite; approved versions include semaglutide and tirzepatide, sold under brand names such as Wegovy, Ozempic, Zepbound, and Mounjaro. Compounded versions are custom-made copies prepared by pharmacies or outsourcing facilities, not generic drugs approved through the FDA’s standard process. (fda.gov) The crackdown comes after months of booming demand and shortages that pushed patients toward lower-cost compounded products sold through telehealth sites and medical spas. On April 1, the FDA said national GLP-1 supply was beginning to stabilize and reminded compounders that federal exemptions apply only under specific conditions. (fda.gov) In a separate February announcement, the FDA said it plans to restrict active pharmaceutical ingredients used in non-FDA-approved compounded GLP-1 drugs that are being mass-marketed as alternatives to approved products. The agency said those steps could include adding ingredients to lists that would block or limit their use in compounding. (fda.gov) The FDA also said marketers cannot present compounded GLP-1s as “generic,” “equivalent,” or capable of producing the same results as approved drugs, and it said enforcement options include seizure and injunction. (ajmc.com) The safety concerns extend beyond advertising. An FDA page updated this year says the agency has received reports involving dosing errors, hospitalizations tied to compounded semaglutide, and products made with salt forms or other ingredients that differ from the approved drugs. (fda.gov) A recent “secret shopper” study described by Medscape found some compounded GLP-1 sellers offered products with added ingredients and raised questions about sterility practices, while a Healio report on the same study said researchers contacted clinics and med spas in two states posing as customers. (medscape.com, healio.com) Drugmakers have also pressed the issue. Fierce Pharma reported in March that Eli Lilly said its testing found high levels of an impurity in some compounded tirzepatide products containing vitamin B12, though that claim came from the manufacturer, not an FDA finding. (fiercepharma.com) The companies that received warning letters now have to decide whether to change their marketing, their formulations, or both. The FDA’s message is narrower than a ban on all compounding, but it draws a bright line against mass-market copycats sold like approved drugs. (fda.gov, fda.gov)